Around the time of the publication of the pair of genetic studies linking LRRK2 to PD, an economic report predicted that the cost for the development of a new therapeutic would cost over $1 billion USD over a 10- to 15-year period, from preclinical work through phase clinical trial.64 But PD fits poorly into this optimistic mold. Here, LRRK2 is linked to Parkinson disease.